| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Opioid, kappa | 21 | 2017 | 134 | 3.680 |
Why?
|
| Bipolar Disorder | 83 | 2020 | 5130 | 3.380 |
Why?
|
| Psychotic Disorders | 50 | 2024 | 3275 | 2.780 |
Why?
|
| Schizophrenia | 73 | 2022 | 6977 | 2.410 |
Why?
|
| Diterpenes | 9 | 2009 | 169 | 2.090 |
Why?
|
| Antipsychotic Agents | 55 | 2022 | 3078 | 2.060 |
Why?
|
| Diterpenes, Clerodane | 15 | 2011 | 42 | 2.000 |
Why?
|
| Antidepressive Agents | 22 | 2024 | 2912 | 1.630 |
Why?
|
| Clozapine | 17 | 2022 | 509 | 1.610 |
Why?
|
| Magnetic Resonance Spectroscopy | 50 | 2017 | 3684 | 1.490 |
Why?
|
| Psychiatry | 6 | 2023 | 1715 | 1.140 |
Why?
|
| Choline | 20 | 2010 | 511 | 1.120 |
Why?
|
| Cocaine | 17 | 2013 | 944 | 1.110 |
Why?
|
| Brain | 70 | 2024 | 27163 | 1.110 |
Why?
|
| Phosphocreatine | 14 | 2017 | 259 | 0.950 |
Why?
|
| Induced Pluripotent Stem Cells | 7 | 2024 | 1882 | 0.940 |
Why?
|
| S-Adenosylmethionine | 10 | 2014 | 219 | 0.930 |
Why?
|
| Energy Metabolism | 17 | 2022 | 2906 | 0.900 |
Why?
|
| Alzheimer Disease | 17 | 2024 | 8717 | 0.870 |
Why?
|
| Naltrexone | 4 | 2014 | 319 | 0.840 |
Why?
|
| Mood Disorders | 7 | 2014 | 1129 | 0.810 |
Why?
|
| Antimanic Agents | 4 | 2019 | 524 | 0.790 |
Why?
|
| Insurance | 1 | 2023 | 115 | 0.770 |
Why?
|
| Narcotic Antagonists | 4 | 2014 | 591 | 0.760 |
Why?
|
| Depressive Disorder | 28 | 2024 | 3721 | 0.760 |
Why?
|
| Glutamic Acid | 9 | 2017 | 1182 | 0.760 |
Why?
|
| Creatine Kinase | 5 | 2017 | 683 | 0.730 |
Why?
|
| Tetrahydroisoquinolines | 4 | 2017 | 81 | 0.730 |
Why?
|
| Aspartic Acid | 13 | 2015 | 575 | 0.730 |
Why?
|
| Brain Chemistry | 14 | 2014 | 951 | 0.700 |
Why?
|
| Neuroglia | 4 | 2014 | 960 | 0.660 |
Why?
|
| Psychotropic Drugs | 10 | 2017 | 881 | 0.620 |
Why?
|
| Hallucinations | 9 | 2021 | 373 | 0.620 |
Why?
|
| Acetamides | 2 | 2012 | 259 | 0.610 |
Why?
|
| Adenosine Triphosphate | 6 | 2017 | 2001 | 0.600 |
Why?
|
| Schizophrenic Psychology | 14 | 2018 | 1647 | 0.590 |
Why?
|
| Depressive Disorder, Major | 10 | 2024 | 4813 | 0.580 |
Why?
|
| Rats, Sprague-Dawley | 35 | 2015 | 8108 | 0.570 |
Why?
|
| Electroconvulsive Therapy | 2 | 2022 | 505 | 0.560 |
Why?
|
| Behavior, Animal | 10 | 2011 | 1865 | 0.540 |
Why?
|
| Cytidine | 3 | 2012 | 60 | 0.540 |
Why?
|
| Ubiquinone | 2 | 2015 | 181 | 0.530 |
Why?
|
| Affect | 11 | 2016 | 1494 | 0.530 |
Why?
|
| Morphinans | 2 | 2013 | 27 | 0.520 |
Why?
|
| Psychiatric Status Rating Scales | 37 | 2024 | 6023 | 0.520 |
Why?
|
| Haloperidol | 13 | 2006 | 394 | 0.510 |
Why?
|
| Valproic Acid | 5 | 2012 | 444 | 0.510 |
Why?
|
| Proto-Oncogene Proteins c-fos | 11 | 2011 | 582 | 0.510 |
Why?
|
| Amygdala | 5 | 2016 | 1375 | 0.500 |
Why?
|
| Nucleus Accumbens | 5 | 2011 | 360 | 0.480 |
Why?
|
| Guanidines | 2 | 2013 | 194 | 0.480 |
Why?
|
| Thyrotropin | 2 | 2018 | 834 | 0.470 |
Why?
|
| Oligodendroglia | 1 | 2018 | 539 | 0.470 |
Why?
|
| Mental Disorders | 8 | 2022 | 6873 | 0.470 |
Why?
|
| Prefrontal Cortex | 8 | 2019 | 2224 | 0.450 |
Why?
|
| Rats | 48 | 2015 | 23713 | 0.450 |
Why?
|
| Acetylcarnitine | 1 | 2013 | 9 | 0.450 |
Why?
|
| Functional Laterality | 9 | 2017 | 2245 | 0.450 |
Why?
|
| Humans | 265 | 2024 | 767040 | 0.450 |
Why?
|
| Thioctic Acid | 1 | 2013 | 28 | 0.440 |
Why?
|
| Magnetic Field Therapy | 1 | 2013 | 27 | 0.440 |
Why?
|
| Mitochondria | 8 | 2021 | 3678 | 0.430 |
Why?
|
| Panic Disorder | 3 | 2014 | 613 | 0.430 |
Why?
|
| Hypothyroidism | 1 | 2018 | 667 | 0.430 |
Why?
|
| Reward | 4 | 2014 | 980 | 0.420 |
Why?
|
| Dopamine | 6 | 2007 | 1581 | 0.420 |
Why?
|
| Male | 212 | 2024 | 364203 | 0.410 |
Why?
|
| Piperidines | 4 | 2017 | 1667 | 0.410 |
Why?
|
| Salvia | 3 | 2008 | 13 | 0.410 |
Why?
|
| Creatine | 10 | 2010 | 424 | 0.390 |
Why?
|
| Prosencephalon | 3 | 2003 | 305 | 0.390 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 1089 | 0.390 |
Why?
|
| Periodicals as Topic | 1 | 2022 | 1465 | 0.380 |
Why?
|
| Adult | 153 | 2024 | 223317 | 0.380 |
Why?
|
| Receptors, Dopamine D2 | 5 | 2006 | 471 | 0.370 |
Why?
|
| Fluoxetine | 10 | 2008 | 733 | 0.370 |
Why?
|
| Astrocytes | 4 | 2014 | 1352 | 0.350 |
Why?
|
| Triazines | 1 | 2012 | 311 | 0.350 |
Why?
|
| Neurons | 15 | 2022 | 9517 | 0.340 |
Why?
|
| Phospholipids | 4 | 2010 | 778 | 0.320 |
Why?
|
| Frontal Lobe | 7 | 2017 | 1408 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 42 | 2021 | 36582 | 0.320 |
Why?
|
| Double-Blind Method | 19 | 2014 | 12451 | 0.320 |
Why?
|
| Self Stimulation | 5 | 2012 | 46 | 0.310 |
Why?
|
| Central Nervous System Agents | 1 | 2009 | 71 | 0.310 |
Why?
|
| Dementia | 4 | 2023 | 2741 | 0.310 |
Why?
|
| Structure-Activity Relationship | 8 | 2011 | 3052 | 0.310 |
Why?
|
| Basal Ganglia | 7 | 2020 | 549 | 0.310 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2013 | 1139 | 0.310 |
Why?
|
| Depression | 9 | 2019 | 8234 | 0.300 |
Why?
|
| Thioridazine | 8 | 1998 | 33 | 0.300 |
Why?
|
| Immediate-Early Proteins | 4 | 1997 | 444 | 0.300 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 8 | 2021 | 1987 | 0.300 |
Why?
|
| Pentazocine | 1 | 2007 | 12 | 0.300 |
Why?
|
| Sertraline | 1 | 2009 | 210 | 0.300 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2012 | 1399 | 0.300 |
Why?
|
| Furans | 1 | 2008 | 199 | 0.290 |
Why?
|
| Female | 156 | 2024 | 396660 | 0.280 |
Why?
|
| Synaptic Transmission | 6 | 2016 | 1175 | 0.280 |
Why?
|
| Cerebrovascular Circulation | 12 | 2003 | 2672 | 0.280 |
Why?
|
| NAD | 3 | 2022 | 618 | 0.280 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2006 | 29 | 0.270 |
Why?
|
| Corticotropin-Releasing Hormone | 4 | 2012 | 362 | 0.270 |
Why?
|
| Blood Platelets | 14 | 1988 | 2464 | 0.270 |
Why?
|
| Neurotensin | 1 | 2006 | 59 | 0.260 |
Why?
|
| Animals | 74 | 2023 | 168965 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 30 | 2015 | 10748 | 0.260 |
Why?
|
| Phosphorus Isotopes | 5 | 2017 | 125 | 0.260 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2006 | 42 | 0.260 |
Why?
|
| Middle Aged | 97 | 2024 | 223233 | 0.260 |
Why?
|
| Gyrus Cinguli | 7 | 2017 | 1118 | 0.260 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2006 | 64 | 0.260 |
Why?
|
| Biomedical Research | 2 | 2018 | 3464 | 0.260 |
Why?
|
| Kainic Acid | 4 | 2015 | 203 | 0.250 |
Why?
|
| Injections, Intraperitoneal | 4 | 2012 | 411 | 0.250 |
Why?
|
| Hospitals, Psychiatric | 1 | 2007 | 317 | 0.250 |
Why?
|
| Binding, Competitive | 3 | 2005 | 1141 | 0.250 |
Why?
|
| Temporal Lobe | 7 | 2021 | 1717 | 0.250 |
Why?
|
| Phosphatidylcholines | 4 | 2016 | 405 | 0.250 |
Why?
|
| Affective Disorders, Psychotic | 4 | 2000 | 187 | 0.250 |
Why?
|
| Radioligand Assay | 14 | 2007 | 365 | 0.240 |
Why?
|
| Receptors, Dopamine | 6 | 2007 | 291 | 0.240 |
Why?
|
| Thalamus | 3 | 2005 | 1040 | 0.240 |
Why?
|
| Signal Transduction | 10 | 2019 | 23621 | 0.240 |
Why?
|
| Plant Leaves | 1 | 2005 | 153 | 0.240 |
Why?
|
| Photic Stimulation | 9 | 2017 | 1989 | 0.230 |
Why?
|
| Young Adult | 28 | 2024 | 59980 | 0.230 |
Why?
|
| Drug Therapy, Combination | 12 | 2019 | 6310 | 0.230 |
Why?
|
| Cognition Disorders | 7 | 2017 | 3968 | 0.230 |
Why?
|
| Caenorhabditis elegans | 5 | 2016 | 1474 | 0.230 |
Why?
|
| Interneurons | 2 | 2019 | 592 | 0.230 |
Why?
|
| Health Behavior | 1 | 2015 | 2650 | 0.230 |
Why?
|
| Echo-Planar Imaging | 5 | 2005 | 648 | 0.220 |
Why?
|
| Case-Control Studies | 18 | 2022 | 22254 | 0.220 |
Why?
|
| Gene Expression | 5 | 2006 | 7587 | 0.220 |
Why?
|
| Health Promotion | 1 | 2015 | 2210 | 0.220 |
Why?
|
| Memory Disorders | 2 | 2010 | 1193 | 0.220 |
Why?
|
| Aging | 7 | 2021 | 8729 | 0.220 |
Why?
|
| Midline Thalamic Nuclei | 1 | 2003 | 14 | 0.220 |
Why?
|
| Delusions | 3 | 2018 | 300 | 0.210 |
Why?
|
| Receptors, Adrenergic, alpha | 5 | 2013 | 146 | 0.210 |
Why?
|
| Administration, Oral | 11 | 2014 | 4026 | 0.210 |
Why?
|
| Pharmacogenetics | 2 | 2024 | 682 | 0.210 |
Why?
|
| Swimming | 6 | 2011 | 212 | 0.210 |
Why?
|
| Anticonvulsants | 2 | 2012 | 1921 | 0.210 |
Why?
|
| Suicide, Attempted | 3 | 2019 | 1413 | 0.210 |
Why?
|
| Pirenzepine | 1 | 2003 | 116 | 0.210 |
Why?
|
| Occipital Lobe | 5 | 2009 | 376 | 0.200 |
Why?
|
| Dynorphins | 1 | 2003 | 82 | 0.200 |
Why?
|
| Carbon | 1 | 2006 | 672 | 0.200 |
Why?
|
| Caudate Nucleus | 4 | 2003 | 388 | 0.200 |
Why?
|
| Molecular Conformation | 3 | 2011 | 540 | 0.200 |
Why?
|
| Fibroblasts | 4 | 2021 | 4167 | 0.200 |
Why?
|
| Glutamine | 3 | 2011 | 575 | 0.200 |
Why?
|
| Cytidine Diphosphate Choline | 3 | 2002 | 29 | 0.200 |
Why?
|
| Myelin Sheath | 2 | 2018 | 649 | 0.200 |
Why?
|
| Antisocial Personality Disorder | 2 | 2022 | 224 | 0.190 |
Why?
|
| Age of Onset | 4 | 2024 | 3344 | 0.190 |
Why?
|
| Sirtuin 2 | 1 | 2021 | 93 | 0.190 |
Why?
|
| Homocysteine | 1 | 2004 | 637 | 0.190 |
Why?
|
| Placebos | 7 | 2004 | 1660 | 0.190 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2003 | 627 | 0.180 |
Why?
|
| Dynamins | 1 | 2021 | 141 | 0.180 |
Why?
|
| Putamen | 3 | 2020 | 288 | 0.180 |
Why?
|
| Taste | 1 | 2002 | 190 | 0.180 |
Why?
|
| Parkinson Disease | 3 | 2023 | 2886 | 0.180 |
Why?
|
| Hydrogen-Ion Concentration | 5 | 2017 | 2478 | 0.180 |
Why?
|
| DiGeorge Syndrome | 1 | 2022 | 187 | 0.180 |
Why?
|
| Cell Membrane | 11 | 1987 | 3642 | 0.180 |
Why?
|
| Benzeneacetamides | 3 | 2013 | 36 | 0.180 |
Why?
|
| Injections, Intravenous | 6 | 2009 | 1377 | 0.170 |
Why?
|
| Publications | 1 | 2022 | 195 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 474 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2007 | 3837 | 0.170 |
Why?
|
| Thalamic Nuclei | 2 | 1998 | 110 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 16036 | 0.170 |
Why?
|
| Akathisia, Drug-Induced | 8 | 1994 | 66 | 0.170 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2021 | 330 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 478 | 0.170 |
Why?
|
| Membrane Fluidity | 8 | 2004 | 67 | 0.170 |
Why?
|
| Amoxapine | 3 | 1984 | 5 | 0.170 |
Why?
|
| Dibenzoxazepines | 3 | 1984 | 8 | 0.170 |
Why?
|
| Zinc Fingers | 4 | 2006 | 577 | 0.170 |
Why?
|
| Personality Disorders | 3 | 2022 | 726 | 0.170 |
Why?
|
| Blood Volume | 6 | 2002 | 543 | 0.160 |
Why?
|
| Caenorhabditis elegans Proteins | 3 | 2016 | 882 | 0.160 |
Why?
|
| Electromagnetic Fields | 3 | 2013 | 290 | 0.160 |
Why?
|
| Phosphorus | 3 | 2015 | 336 | 0.160 |
Why?
|
| CHO Cells | 3 | 2006 | 1376 | 0.160 |
Why?
|
| Follicular Phase | 1 | 1999 | 143 | 0.160 |
Why?
|
| Luteal Phase | 1 | 1999 | 138 | 0.160 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2024 | 1117 | 0.160 |
Why?
|
| Treatment Outcome | 16 | 2022 | 65295 | 0.150 |
Why?
|
| Brain Mapping | 14 | 2021 | 6597 | 0.150 |
Why?
|
| Relaxation | 2 | 2012 | 51 | 0.150 |
Why?
|
| Pyrrolidines | 3 | 2013 | 339 | 0.150 |
Why?
|
| Fish Oils | 1 | 2002 | 483 | 0.150 |
Why?
|
| Purines | 1 | 2001 | 614 | 0.150 |
Why?
|
| Cricetinae | 3 | 2006 | 2415 | 0.150 |
Why?
|
| Tomography, Emission-Computed | 1 | 2000 | 1007 | 0.140 |
Why?
|
| Motor Activity | 8 | 2010 | 2713 | 0.140 |
Why?
|
| Glycolysis | 2 | 2021 | 836 | 0.140 |
Why?
|
| Olfactory Perception | 1 | 2018 | 64 | 0.140 |
Why?
|
| Analysis of Variance | 12 | 2015 | 6215 | 0.140 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 289 | 0.140 |
Why?
|
| Adolescent | 50 | 2017 | 89046 | 0.140 |
Why?
|
| Dyskinesia, Drug-Induced | 3 | 1994 | 165 | 0.140 |
Why?
|
| Parasympatholytics | 2 | 1992 | 89 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 939 | 0.140 |
Why?
|
| Lactosylceramides | 1 | 2016 | 15 | 0.140 |
Why?
|
| Plasmalogens | 1 | 2016 | 30 | 0.140 |
Why?
|
| Oxidation-Reduction | 3 | 2017 | 2221 | 0.140 |
Why?
|
| Mental Recall | 1 | 2023 | 1218 | 0.140 |
Why?
|
| Glucosylceramides | 1 | 2016 | 27 | 0.140 |
Why?
|
| Membrane Lipids | 3 | 1987 | 241 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2023 | 956 | 0.130 |
Why?
|
| Touch Perception | 1 | 2018 | 106 | 0.130 |
Why?
|
| Lithium | 8 | 2006 | 600 | 0.130 |
Why?
|
| Uridine | 2 | 2008 | 135 | 0.130 |
Why?
|
| Aged | 46 | 2020 | 171319 | 0.130 |
Why?
|
| Siblings | 2 | 2018 | 828 | 0.130 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1998 | 619 | 0.130 |
Why?
|
| Genes, fos | 5 | 2008 | 176 | 0.130 |
Why?
|
| Axons | 2 | 2015 | 1675 | 0.130 |
Why?
|
| Blood-Brain Barrier | 3 | 1995 | 1029 | 0.130 |
Why?
|
| Psychopharmacology | 2 | 2007 | 146 | 0.130 |
Why?
|
| Imipramine | 6 | 1989 | 96 | 0.130 |
Why?
|
| Selegiline | 2 | 1996 | 31 | 0.130 |
Why?
|
| Cell Line | 4 | 2022 | 15567 | 0.120 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 97 | 0.120 |
Why?
|
| Time Factors | 28 | 2016 | 40154 | 0.120 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2005 | 491 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 935 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2000 | 1142 | 0.120 |
Why?
|
| Psychomotor Agitation | 7 | 1994 | 307 | 0.120 |
Why?
|
| Rats, Inbred Strains | 9 | 1992 | 2078 | 0.120 |
Why?
|
| Lithium Carbonate | 3 | 2010 | 179 | 0.120 |
Why?
|
| Cocaine-Related Disorders | 3 | 2007 | 458 | 0.120 |
Why?
|
| Ketamine | 2 | 2011 | 527 | 0.110 |
Why?
|
| Polymorphism, Genetic | 3 | 2006 | 4247 | 0.110 |
Why?
|
| Genes, Immediate-Early | 1 | 1994 | 102 | 0.110 |
Why?
|
| Cadherins | 1 | 2019 | 903 | 0.110 |
Why?
|
| Glycine | 1 | 2017 | 670 | 0.110 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2015 | 88 | 0.110 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2016 | 265 | 0.110 |
Why?
|
| Organoids | 1 | 2020 | 740 | 0.110 |
Why?
|
| Fluphenazine | 4 | 1986 | 35 | 0.110 |
Why?
|
| Linear Models | 3 | 2013 | 5875 | 0.110 |
Why?
|
| Acute Disease | 7 | 2019 | 7236 | 0.110 |
Why?
|
| Age Factors | 11 | 2018 | 18401 | 0.110 |
Why?
|
| Auditory Perception | 1 | 2018 | 586 | 0.110 |
Why?
|
| Self Administration | 2 | 2015 | 386 | 0.110 |
Why?
|
| Ethanol | 3 | 2014 | 1330 | 0.110 |
Why?
|
| Inositol | 4 | 2004 | 216 | 0.110 |
Why?
|
| Attention | 3 | 2016 | 2413 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2457 | 0.100 |
Why?
|
| TRPM Cation Channels | 1 | 2014 | 140 | 0.100 |
Why?
|
| ATP Synthetase Complexes | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cerebral Cortex | 5 | 2011 | 5754 | 0.100 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2003 | 74 | 0.100 |
Why?
|
| Paroxetine | 3 | 2003 | 181 | 0.100 |
Why?
|
| Reference Values | 7 | 2008 | 4918 | 0.100 |
Why?
|
| Neurologic Examination | 2 | 2002 | 913 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2020 | 895 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 616 | 0.100 |
Why?
|
| Maze Learning | 2 | 2015 | 480 | 0.100 |
Why?
|
| Reinforcement Schedule | 1 | 2012 | 123 | 0.100 |
Why?
|
| LLC-PK1 Cells | 1 | 2012 | 125 | 0.100 |
Why?
|
| Cerebellum | 4 | 2021 | 1521 | 0.100 |
Why?
|
| Electrophysiology | 1 | 2015 | 1263 | 0.100 |
Why?
|
| Social Behavior | 2 | 2017 | 1147 | 0.100 |
Why?
|
| Kinetics | 6 | 2013 | 6287 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 3 | 2020 | 4401 | 0.100 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 2 | 2013 | 66 | 0.100 |
Why?
|
| Captopril | 2 | 1991 | 261 | 0.090 |
Why?
|
| Rest | 1 | 2016 | 941 | 0.090 |
Why?
|
| Neuropsychological Tests | 7 | 2016 | 7121 | 0.090 |
Why?
|
| Meperidine | 1 | 1991 | 37 | 0.090 |
Why?
|
| Apomorphine | 3 | 1992 | 148 | 0.090 |
Why?
|
| Glutaminase | 1 | 2011 | 31 | 0.090 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2022 | 903 | 0.090 |
Why?
|
| Gene Expression Regulation | 6 | 2010 | 11923 | 0.090 |
Why?
|
| Early Growth Response Protein 1 | 4 | 1997 | 133 | 0.090 |
Why?
|
| Biological Transport | 2 | 2013 | 2084 | 0.090 |
Why?
|
| Protons | 5 | 2011 | 1101 | 0.090 |
Why?
|
| Neuronal Plasticity | 3 | 2016 | 1446 | 0.090 |
Why?
|
| Parietal Lobe | 3 | 2013 | 861 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 326 | 0.090 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 391 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2017 | 4526 | 0.090 |
Why?
|
| Drug Administration Schedule | 6 | 2007 | 4855 | 0.090 |
Why?
|
| Anti-Anxiety Agents | 1 | 2013 | 405 | 0.090 |
Why?
|
| Phenothiazines | 5 | 1992 | 60 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2006 | 2472 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2005 | 1331 | 0.090 |
Why?
|
| Permeability | 1 | 2012 | 721 | 0.090 |
Why?
|
| Propranolol | 4 | 1984 | 493 | 0.090 |
Why?
|
| Fluorine | 2 | 2000 | 78 | 0.090 |
Why?
|
| Anxiety Disorders | 3 | 2012 | 2745 | 0.090 |
Why?
|
| Disease Models, Animal | 9 | 2023 | 18330 | 0.080 |
Why?
|
| Papio anubis | 1 | 2009 | 23 | 0.080 |
Why?
|
| Fluorescence Polarization | 7 | 1987 | 139 | 0.080 |
Why?
|
| Cytochromes c | 1 | 2010 | 173 | 0.080 |
Why?
|
| Comorbidity | 4 | 2016 | 10582 | 0.080 |
Why?
|
| Receptors, Nicotinic | 1 | 2013 | 494 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 3431 | 0.080 |
Why?
|
| Riluzole | 1 | 2009 | 62 | 0.080 |
Why?
|
| Pilot Projects | 6 | 2015 | 8732 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 2144 | 0.080 |
Why?
|
| Insulin | 2 | 2018 | 6602 | 0.080 |
Why?
|
| Metabolome | 1 | 2016 | 1008 | 0.080 |
Why?
|
| Lung Diseases, Obstructive | 3 | 1984 | 309 | 0.080 |
Why?
|
| Health Personnel | 1 | 2023 | 3387 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2016 | 1407 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 3700 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1989 | 243 | 0.080 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2015 | 2421 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 1997 | 6067 | 0.080 |
Why?
|
| Respiratory Therapy | 4 | 1982 | 124 | 0.080 |
Why?
|
| Conditioning, Operant | 1 | 2010 | 306 | 0.080 |
Why?
|
| Auditory Cortex | 1 | 2012 | 366 | 0.080 |
Why?
|
| Water | 2 | 2012 | 1419 | 0.080 |
Why?
|
| Neurogenesis | 1 | 2015 | 863 | 0.080 |
Why?
|
| Common Cold | 2 | 1982 | 63 | 0.080 |
Why?
|
| Severity of Illness Index | 9 | 2018 | 15925 | 0.080 |
Why?
|
| Lovastatin | 1 | 2008 | 114 | 0.080 |
Why?
|
| Medial Forebrain Bundle | 1 | 2008 | 42 | 0.080 |
Why?
|
| Nootropic Agents | 2 | 2002 | 159 | 0.080 |
Why?
|
| Vasoconstriction | 3 | 2001 | 591 | 0.080 |
Why?
|
| Walking | 1 | 2015 | 1201 | 0.080 |
Why?
|
| Research Design | 2 | 2016 | 6210 | 0.080 |
Why?
|
| Appetite Depressants | 2 | 1999 | 108 | 0.070 |
Why?
|
| Carbon Radioisotopes | 1 | 2009 | 544 | 0.070 |
Why?
|
| Basal Ganglia Diseases | 3 | 1996 | 145 | 0.070 |
Why?
|
| Chlorpromazine | 3 | 1986 | 111 | 0.070 |
Why?
|
| RNA Interference | 2 | 2014 | 2829 | 0.070 |
Why?
|
| Ethers | 1 | 2007 | 72 | 0.070 |
Why?
|
| Microsomes, Liver | 1 | 2007 | 174 | 0.070 |
Why?
|
| Raphe Nuclei | 1 | 2007 | 104 | 0.070 |
Why?
|
| Alcohols | 1 | 2007 | 94 | 0.070 |
Why?
|
| Marital Status | 2 | 2018 | 426 | 0.070 |
Why?
|
| Circadian Rhythm | 3 | 2017 | 2591 | 0.070 |
Why?
|
| Norepinephrine | 4 | 2013 | 898 | 0.070 |
Why?
|
| Acetylcholine | 2 | 2003 | 628 | 0.070 |
Why?
|
| Euphoria | 1 | 2007 | 64 | 0.070 |
Why?
|
| Electroshock | 1 | 2007 | 120 | 0.070 |
Why?
|
| Visual Perception | 3 | 2019 | 1392 | 0.070 |
Why?
|
| Hippocampus | 3 | 2015 | 3777 | 0.070 |
Why?
|
| Heterocyclic Compounds | 3 | 2001 | 245 | 0.070 |
Why?
|
| Smell | 1 | 2009 | 259 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2015 | 1168 | 0.070 |
Why?
|
| Touch | 1 | 2009 | 313 | 0.070 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2008 | 286 | 0.070 |
Why?
|
| Alprazolam | 1 | 1986 | 103 | 0.070 |
Why?
|
| Narcotics | 2 | 1999 | 332 | 0.070 |
Why?
|
| Airway Resistance | 5 | 1982 | 407 | 0.070 |
Why?
|
| Genome-Wide Association Study | 3 | 2015 | 12790 | 0.070 |
Why?
|
| Visual Cortex | 3 | 2002 | 1081 | 0.070 |
Why?
|
| Mice | 11 | 2023 | 81912 | 0.070 |
Why?
|
| Diphenylhexatriene | 7 | 1987 | 12 | 0.070 |
Why?
|
| Transcription Factors | 7 | 2013 | 12158 | 0.070 |
Why?
|
| Half-Life | 3 | 1993 | 648 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2012 | 2658 | 0.070 |
Why?
|
| Larva | 3 | 2014 | 512 | 0.070 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 951 | 0.060 |
Why?
|
| Fear | 4 | 2015 | 1496 | 0.060 |
Why?
|
| Depression, Chemical | 1 | 2005 | 186 | 0.060 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 87 | 0.060 |
Why?
|
| Septal Nuclei | 1 | 2006 | 82 | 0.060 |
Why?
|
| Lung Volume Measurements | 2 | 1984 | 381 | 0.060 |
Why?
|
| Mitochondrial Diseases | 1 | 2009 | 344 | 0.060 |
Why?
|
| Cell Count | 2 | 2007 | 1825 | 0.060 |
Why?
|
| Aerosols | 4 | 1982 | 634 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2017 | 8940 | 0.060 |
Why?
|
| Microdialysis | 1 | 2005 | 156 | 0.060 |
Why?
|
| Molecular Structure | 2 | 2007 | 1882 | 0.060 |
Why?
|
| Esters | 1 | 2006 | 212 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3139 | 0.060 |
Why?
|
| Cytoskeleton | 1 | 2010 | 1178 | 0.060 |
Why?
|
| Formates | 1 | 2004 | 37 | 0.060 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2005 | 121 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2004 | 1429 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2018 | 13048 | 0.060 |
Why?
|
| Regression Analysis | 5 | 2015 | 6331 | 0.060 |
Why?
|
| Social Support | 1 | 2015 | 2192 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2007 | 714 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 464 | 0.060 |
Why?
|
| Amines | 1 | 2006 | 280 | 0.060 |
Why?
|
| Cricetulus | 1 | 2006 | 810 | 0.060 |
Why?
|
| Parvalbumins | 1 | 2006 | 256 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2020 | 11657 | 0.060 |
Why?
|
| Overweight | 1 | 2016 | 2448 | 0.060 |
Why?
|
| Organometallic Compounds | 3 | 2001 | 648 | 0.060 |
Why?
|
| Serotonin | 2 | 2007 | 1045 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 4 | 1988 | 694 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 2744 | 0.060 |
Why?
|
| Vocabulary | 1 | 2005 | 166 | 0.060 |
Why?
|
| Cycloserine | 1 | 2005 | 118 | 0.060 |
Why?
|
| Marijuana Abuse | 1 | 2008 | 409 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2006 | 11063 | 0.060 |
Why?
|
| Models, Psychological | 2 | 2024 | 823 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 2883 | 0.060 |
Why?
|
| Legislation, Drug | 1 | 1986 | 216 | 0.060 |
Why?
|
| Drug Design | 1 | 2009 | 1045 | 0.060 |
Why?
|
| Self Report | 1 | 2015 | 3773 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2011 | 1244 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 4968 | 0.060 |
Why?
|
| Biological Availability | 1 | 2004 | 387 | 0.060 |
Why?
|
| Asbestosis | 1 | 1984 | 81 | 0.060 |
Why?
|
| Family | 1 | 2014 | 3210 | 0.060 |
Why?
|
| Extracellular Space | 1 | 2005 | 563 | 0.050 |
Why?
|
| Sex Factors | 9 | 2015 | 10622 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2023 | 42 | 0.050 |
Why?
|
| Amides | 1 | 2006 | 451 | 0.050 |
Why?
|
| Blood Viscosity | 1 | 1984 | 125 | 0.050 |
Why?
|
| Reproducibility of Results | 5 | 2012 | 20169 | 0.050 |
Why?
|
| Conditioning, Classical | 1 | 2006 | 368 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2019 | 14476 | 0.050 |
Why?
|
| Enkephalin, Methionine | 1 | 2003 | 26 | 0.050 |
Why?
|
| Diphenhydramine | 1 | 2003 | 61 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2004 | 360 | 0.050 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2003 | 18 | 0.050 |
Why?
|
| Acetylation | 2 | 2021 | 1055 | 0.050 |
Why?
|
| Endophenotypes | 2 | 2015 | 258 | 0.050 |
Why?
|
| Limbic System | 1 | 2005 | 418 | 0.050 |
Why?
|
| Electric Stimulation | 3 | 2015 | 1736 | 0.050 |
Why?
|
| Models, Neurological | 2 | 2010 | 1747 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 3610 | 0.050 |
Why?
|
| Psychometrics | 1 | 2012 | 3060 | 0.050 |
Why?
|
| Anxiety | 2 | 2015 | 4670 | 0.050 |
Why?
|
| Pyridinium Compounds | 1 | 2022 | 80 | 0.050 |
Why?
|
| Lorazepam | 1 | 2003 | 155 | 0.050 |
Why?
|
| Ligands | 1 | 2009 | 3273 | 0.050 |
Why?
|
| Hospitalization | 3 | 2000 | 10815 | 0.050 |
Why?
|
| Swine | 1 | 2012 | 5987 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2001 | 107 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2005 | 496 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2007 | 1029 | 0.050 |
Why?
|
| Genome, Human | 1 | 2015 | 4441 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2024 | 1002 | 0.050 |
Why?
|
| Multiple System Atrophy | 1 | 2003 | 132 | 0.050 |
Why?
|
| Suicide | 1 | 2013 | 1606 | 0.050 |
Why?
|
| Phosphates | 2 | 2003 | 765 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 18063 | 0.050 |
Why?
|
| Recurrence | 4 | 2007 | 8504 | 0.050 |
Why?
|
| Cholesterol | 3 | 1987 | 2905 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2006 | 5022 | 0.050 |
Why?
|
| Hemodilution | 1 | 2001 | 120 | 0.050 |
Why?
|
| Sleep | 1 | 2017 | 4816 | 0.050 |
Why?
|
| Mesencephalon | 1 | 2023 | 338 | 0.050 |
Why?
|
| Tissue Distribution | 3 | 2012 | 2275 | 0.050 |
Why?
|
| AIDS Dementia Complex | 1 | 2002 | 154 | 0.050 |
Why?
|
| Plant Oils | 1 | 2002 | 199 | 0.050 |
Why?
|
| Massachusetts | 3 | 2016 | 8890 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 4045 | 0.050 |
Why?
|
| Mutation | 4 | 2022 | 30211 | 0.040 |
Why?
|
| Bronchitis | 3 | 1972 | 193 | 0.040 |
Why?
|
| Oxygen | 4 | 2001 | 4252 | 0.040 |
Why?
|
| Neurocan | 1 | 2020 | 21 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2003 | 270 | 0.040 |
Why?
|
| Respiration | 3 | 1977 | 1655 | 0.040 |
Why?
|
| Restless Legs Syndrome | 1 | 1983 | 235 | 0.040 |
Why?
|
| Wakefulness | 1 | 2007 | 1282 | 0.040 |
Why?
|
| Aged, 80 and over | 9 | 2010 | 59548 | 0.040 |
Why?
|
| Verbal Behavior | 2 | 2005 | 328 | 0.040 |
Why?
|
| Hematocrit | 1 | 2001 | 622 | 0.040 |
Why?
|
| Niacinamide | 1 | 2022 | 417 | 0.040 |
Why?
|
| Speech | 1 | 2005 | 555 | 0.040 |
Why?
|
| Dexfenfluramine | 1 | 1999 | 8 | 0.040 |
Why?
|
| Sympatholytics | 1 | 1979 | 82 | 0.040 |
Why?
|
| Desipramine | 3 | 2005 | 183 | 0.040 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2020 | 142 | 0.040 |
Why?
|
| Informed Consent | 2 | 2002 | 1010 | 0.040 |
Why?
|
| Dopamine Antagonists | 2 | 1988 | 279 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 501 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2000 | 326 | 0.040 |
Why?
|
| Phosphorylcholine | 2 | 2002 | 152 | 0.040 |
Why?
|
| Methadone | 2 | 1999 | 317 | 0.040 |
Why?
|
| Teaching | 1 | 2007 | 1172 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1992 | 1531 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2007 | 2765 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 6550 | 0.040 |
Why?
|
| Epilepsy | 1 | 1994 | 3317 | 0.040 |
Why?
|
| Clinical Trials as Topic | 10 | 2024 | 8048 | 0.040 |
Why?
|
| Neural Inhibition | 1 | 2003 | 589 | 0.040 |
Why?
|
| Chromans | 1 | 1979 | 116 | 0.040 |
Why?
|
| Benzopyrans | 1 | 1979 | 63 | 0.040 |
Why?
|
| Brain Waves | 2 | 2013 | 416 | 0.040 |
Why?
|
| Heart Rate | 3 | 1999 | 4209 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2014 | 3792 | 0.040 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 39317 | 0.040 |
Why?
|
| Norfenfluramine | 1 | 1998 | 1 | 0.040 |
Why?
|
| Bronchodilator Agents | 3 | 1977 | 513 | 0.040 |
Why?
|
| Cognition | 1 | 2016 | 7059 | 0.040 |
Why?
|
| Salicylamides | 1 | 1998 | 31 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2003 | 3370 | 0.040 |
Why?
|
| Receptors, Dopamine D4 | 1 | 1999 | 168 | 0.040 |
Why?
|
| Fenfluramine | 1 | 1998 | 58 | 0.040 |
Why?
|
| Raclopride | 1 | 1998 | 98 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2212 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 2010 | 1987 | 0.040 |
Why?
|
| Length of Stay | 4 | 2000 | 6489 | 0.040 |
Why?
|
| Caffeine | 1 | 2022 | 703 | 0.040 |
Why?
|
| Corpus Striatum | 2 | 1995 | 1217 | 0.040 |
Why?
|
| Menstrual Cycle | 1 | 2001 | 546 | 0.040 |
Why?
|
| Gadolinium | 3 | 2001 | 964 | 0.040 |
Why?
|
| Syndrome | 2 | 2003 | 3271 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2020 | 18989 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2018 | 1458 | 0.040 |
Why?
|
| Superior Cervical Ganglion | 1 | 2016 | 33 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2003 | 1137 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2020 | 1085 | 0.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2015 | 3724 | 0.030 |
Why?
|
| Cyclothymic Disorder | 1 | 2016 | 42 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2020 | 591 | 0.030 |
Why?
|
| Alleles | 3 | 2013 | 6893 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 222 | 0.030 |
Why?
|
| Naloxone | 1 | 1979 | 372 | 0.030 |
Why?
|
| Species Specificity | 2 | 2011 | 2412 | 0.030 |
Why?
|
| Stereotyped Behavior | 2 | 1992 | 133 | 0.030 |
Why?
|
| DNA-Binding Proteins | 4 | 1997 | 9612 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2011 | 501 | 0.030 |
Why?
|
| Drug Interactions | 2 | 2011 | 1419 | 0.030 |
Why?
|
| Genetic Variation | 3 | 2013 | 6611 | 0.030 |
Why?
|
| Dexamethasone | 4 | 2016 | 1963 | 0.030 |
Why?
|
| Lithium Chloride | 1 | 1996 | 83 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 369 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2005 | 429 | 0.030 |
Why?
|
| Prolactin | 3 | 1984 | 627 | 0.030 |
Why?
|
| Catatonia | 1 | 2019 | 181 | 0.030 |
Why?
|
| Inpatients | 1 | 2007 | 2563 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 16718 | 0.030 |
Why?
|
| Pulmonary Emphysema | 3 | 1972 | 689 | 0.030 |
Why?
|
| Cosmetics | 1 | 1977 | 104 | 0.030 |
Why?
|
| Risperidone | 1 | 1998 | 383 | 0.030 |
Why?
|
| Cohort Studies | 7 | 2018 | 41718 | 0.030 |
Why?
|
| Synapses | 2 | 2019 | 1759 | 0.030 |
Why?
|
| Glucose | 2 | 2018 | 4341 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 22361 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 5796 | 0.030 |
Why?
|
| Glycerylphosphorylcholine | 1 | 1995 | 25 | 0.030 |
Why?
|
| Erythrocytes | 3 | 1991 | 2411 | 0.030 |
Why?
|
| Antitussive Agents | 1 | 1975 | 19 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2016 | 369 | 0.030 |
Why?
|
| Social Adjustment | 1 | 2017 | 634 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2118 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 17097 | 0.030 |
Why?
|
| Progesterone | 1 | 1999 | 752 | 0.030 |
Why?
|
| Facial Expression | 1 | 1999 | 515 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2020 | 2626 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2018 | 529 | 0.030 |
Why?
|
| Protein Binding | 3 | 2013 | 9327 | 0.030 |
Why?
|
| Random Allocation | 2 | 2017 | 2394 | 0.030 |
Why?
|
| Culture Media | 1 | 2016 | 892 | 0.030 |
Why?
|
| G(M1) Ganglioside | 1 | 1994 | 87 | 0.030 |
Why?
|
| Infusions, Intraventricular | 1 | 2014 | 31 | 0.030 |
Why?
|
| Prevalence | 3 | 2019 | 15851 | 0.030 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2014 | 38 | 0.030 |
Why?
|
| RNA | 2 | 2022 | 2715 | 0.030 |
Why?
|
| Quality of Life | 1 | 2015 | 13485 | 0.030 |
Why?
|
| Clonidine | 2 | 1984 | 170 | 0.030 |
Why?
|
| Seizures | 1 | 2007 | 2996 | 0.030 |
Why?
|
| Xenon Radioisotopes | 1 | 1993 | 31 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 12250 | 0.030 |
Why?
|
| Magnesium Sulfate | 1 | 2014 | 73 | 0.030 |
Why?
|
| Pharyngeal Muscles | 1 | 2014 | 81 | 0.030 |
Why?
|
| Brain Damage, Chronic | 1 | 1994 | 265 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3249 | 0.030 |
Why?
|
| Electroencephalography | 3 | 2013 | 6282 | 0.030 |
Why?
|
| Metoprolol | 2 | 1984 | 90 | 0.030 |
Why?
|
| Enkephalins | 2 | 1993 | 139 | 0.030 |
Why?
|
| Receptors, Opioid, delta | 1 | 2013 | 48 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 1902 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2020 | 3093 | 0.030 |
Why?
|
| Nutritional Requirements | 1 | 1995 | 279 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 2745 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1997 | 2176 | 0.030 |
Why?
|
| Neurotransmitter Agents | 2 | 2008 | 661 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 1345 | 0.030 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 1994 | 153 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 1994 | 12793 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2014 | 624 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 6226 | 0.030 |
Why?
|
| Disease Progression | 1 | 2010 | 13646 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2015 | 590 | 0.030 |
Why?
|
| Borderline Personality Disorder | 3 | 1985 | 767 | 0.030 |
Why?
|
| Biotransformation | 1 | 1992 | 165 | 0.030 |
Why?
|
| Genotype | 4 | 2013 | 13035 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 414 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2013 | 364 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2008 | 1759 | 0.030 |
Why?
|
| Eggs | 1 | 2014 | 182 | 0.030 |
Why?
|
| Neuropsychiatry | 1 | 2013 | 76 | 0.030 |
Why?
|
| Butyrophenones | 1 | 1992 | 15 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2012 | 227 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2013 | 3621 | 0.020 |
Why?
|
| Expectorants | 1 | 1972 | 22 | 0.020 |
Why?
|
| Receptors, Opioid, mu | 1 | 2013 | 167 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 161 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2012 | 142 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 2698 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 361 | 0.020 |
Why?
|
| Estradiol | 1 | 1999 | 1951 | 0.020 |
Why?
|
| Chromatography, Gas | 1 | 1992 | 150 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 2013 | 424 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 20741 | 0.020 |
Why?
|
| Clomipramine | 1 | 1991 | 50 | 0.020 |
Why?
|
| Dextroamphetamine | 1 | 1992 | 132 | 0.020 |
Why?
|
| Sucrose | 1 | 2012 | 156 | 0.020 |
Why?
|
| Oviposition | 1 | 2011 | 22 | 0.020 |
Why?
|
| Biogenic Amines | 1 | 2011 | 53 | 0.020 |
Why?
|
| Chronic Disease | 6 | 2010 | 9362 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 4838 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2002 | 2867 | 0.020 |
Why?
|
| Maximal Expiratory Flow-Volume Curves | 2 | 1984 | 25 | 0.020 |
Why?
|
| Respiratory Function Tests | 2 | 1977 | 1695 | 0.020 |
Why?
|
| Reaction Time | 2 | 2010 | 2086 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10455 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2014 | 839 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 1995 | 748 | 0.020 |
Why?
|
| Base Sequence | 5 | 2006 | 12414 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2005 | 12069 | 0.020 |
Why?
|
| Nicotinic Agonists | 1 | 2013 | 265 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 1478 | 0.020 |
Why?
|
| Prognosis | 3 | 2015 | 29963 | 0.020 |
Why?
|
| Cough | 1 | 1975 | 598 | 0.020 |
Why?
|
| Phenylephrine | 3 | 1982 | 292 | 0.020 |
Why?
|
| Prazosin | 2 | 1988 | 95 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 606 | 0.020 |
Why?
|
| Hindlimb Suspension | 1 | 2011 | 77 | 0.020 |
Why?
|
| Color | 1 | 1972 | 296 | 0.020 |
Why?
|
| Ultrasonics | 1 | 1972 | 208 | 0.020 |
Why?
|
| Vital Capacity | 3 | 1984 | 996 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2000 | 10092 | 0.020 |
Why?
|
| Health Status | 1 | 2003 | 4091 | 0.020 |
Why?
|
| Magnesium | 1 | 2014 | 815 | 0.020 |
Why?
|
| Educational Status | 1 | 2018 | 2511 | 0.020 |
Why?
|
| Spirometry | 4 | 1977 | 928 | 0.020 |
Why?
|
| Triglycerides | 1 | 2018 | 2444 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1443 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2011 | 313 | 0.020 |
Why?
|
| Blood Vessels | 1 | 1995 | 1110 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 804 | 0.020 |
Why?
|
| Leptin | 1 | 2018 | 1599 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 26325 | 0.020 |
Why?
|
| Nervous System | 1 | 1993 | 543 | 0.020 |
Why?
|
| Protein Precursors | 2 | 1993 | 1134 | 0.020 |
Why?
|
| Phenelzine | 2 | 1988 | 28 | 0.020 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1989 | 74 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2012 | 810 | 0.020 |
Why?
|
| Creatinine | 1 | 1995 | 1916 | 0.020 |
Why?
|
| Memory | 1 | 1999 | 2192 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2014 | 1562 | 0.020 |
Why?
|
| Nose | 2 | 1970 | 522 | 0.020 |
Why?
|
| Catalepsy | 3 | 1988 | 31 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1999 | 2647 | 0.020 |
Why?
|
| Food Preferences | 1 | 2012 | 397 | 0.020 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 1886 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 1994 | 1459 | 0.020 |
Why?
|
| Stereoisomerism | 2 | 2005 | 612 | 0.020 |
Why?
|
| Body Composition | 1 | 2018 | 2454 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2010 | 443 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 1997 | 13411 | 0.020 |
Why?
|
| Single-Blind Method | 3 | 2001 | 1587 | 0.020 |
Why?
|
| Cattle | 3 | 1984 | 3813 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 285 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 15424 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2009 | 375 | 0.020 |
Why?
|
| Blood Pressure | 3 | 1999 | 8531 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2013 | 2602 | 0.020 |
Why?
|
| Efferent Pathways | 1 | 2007 | 164 | 0.020 |
Why?
|
| Carbamazepine | 1 | 1988 | 224 | 0.020 |
Why?
|
| Tranquilizing Agents | 1 | 1987 | 59 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2016 | 2163 | 0.020 |
Why?
|
| Phantoms, Imaging | 3 | 2002 | 2487 | 0.020 |
Why?
|
| Electromyography | 1 | 2012 | 1398 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 2721 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1987 | 171 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2007 | 5947 | 0.020 |
Why?
|
| Acetates | 1 | 2008 | 314 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 310 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 3587 | 0.020 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1987 | 177 | 0.020 |
Why?
|
| Parasympathomimetics | 1 | 1986 | 28 | 0.020 |
Why?
|
| Pharynx | 1 | 2009 | 436 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 2850 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 1993 | 2201 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1988 | 1623 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1986 | 56 | 0.020 |
Why?
|
| Plethysmography | 3 | 1972 | 172 | 0.020 |
Why?
|
| Erythrocyte Membrane | 1 | 1987 | 438 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2009 | 1160 | 0.020 |
Why?
|
| Parkinson Disease, Secondary | 2 | 1984 | 120 | 0.020 |
Why?
|
| Immobility Response, Tonic | 1 | 2005 | 13 | 0.020 |
Why?
|
| Respiratory System | 1 | 1969 | 563 | 0.020 |
Why?
|
| Freezing Reaction, Cataleptic | 1 | 2005 | 40 | 0.020 |
Why?
|
| Consensus | 1 | 2015 | 3207 | 0.020 |
Why?
|
| Butyrylcholinesterase | 1 | 1985 | 21 | 0.020 |
Why?
|
| Arousal | 2 | 2007 | 1174 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2009 | 839 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2009 | 1526 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2005 | 152 | 0.010 |
Why?
|
| Amitriptyline | 1 | 1985 | 110 | 0.010 |
Why?
|
| Methylation | 1 | 2007 | 1076 | 0.010 |
Why?
|
| Telencephalon | 1 | 2005 | 142 | 0.010 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1985 | 88 | 0.010 |
Why?
|
| Genome | 1 | 2013 | 1752 | 0.010 |
Why?
|
| Cell Survival | 1 | 2014 | 5750 | 0.010 |
Why?
|
| Monoamine Oxidase | 1 | 1985 | 179 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1985 | 94 | 0.010 |
Why?
|
| Galactorrhea | 1 | 1984 | 23 | 0.010 |
Why?
|
| Closing Volume | 1 | 1984 | 3 | 0.010 |
Why?
|
| Transcription, Genetic | 2 | 2006 | 7611 | 0.010 |
Why?
|
| Opioid-Related Disorders | 1 | 1999 | 2188 | 0.010 |
Why?
|
| Alcohol Oxidoreductases | 1 | 1985 | 164 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 2004 | 315 | 0.010 |
Why?
|
| DNA Mutational Analysis | 2 | 2003 | 4114 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2018 | 3986 | 0.010 |
Why?
|
| DNA | 3 | 2006 | 7210 | 0.010 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 1984 | 143 | 0.010 |
Why?
|
| Plethysmography, Whole Body | 2 | 1975 | 25 | 0.010 |
Why?
|
| Colchicine | 1 | 2005 | 256 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2007 | 807 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 1985 | 230 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3114 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1984 | 526 | 0.010 |
Why?
|
| Gout Suppressants | 1 | 2005 | 176 | 0.010 |
Why?
|
| Ambulatory Care | 2 | 2005 | 2780 | 0.010 |
Why?
|
| Reference Standards | 1 | 2007 | 1011 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 2063 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2005 | 514 | 0.010 |
Why?
|
| Body Water | 1 | 2004 | 337 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1985 | 365 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2018 | 6421 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2013 | 2116 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 876 | 0.010 |
Why?
|
| Loxapine | 1 | 1982 | 3 | 0.010 |
Why?
|
| Risk | 2 | 2013 | 9606 | 0.010 |
Why?
|
| California | 1 | 2007 | 1439 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2005 | 423 | 0.010 |
Why?
|
| Cerebral Ventriculography | 1 | 1982 | 44 | 0.010 |
Why?
|
| Tremor | 1 | 1984 | 196 | 0.010 |
Why?
|
| Suicidal Ideation | 1 | 2013 | 1467 | 0.010 |
Why?
|
| Models, Animal | 1 | 2009 | 2121 | 0.010 |
Why?
|
| Eucalyptus | 1 | 1982 | 4 | 0.010 |
Why?
|
| Camphor | 1 | 1982 | 9 | 0.010 |
Why?
|
| Neurosciences | 1 | 2007 | 384 | 0.010 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 1982 | 75 | 0.010 |
Why?
|
| Menthol | 1 | 1982 | 26 | 0.010 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 1991 | 1495 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2008 | 2086 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1985 | 965 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2012 | 3078 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4280 | 0.010 |
Why?
|
| Ethanolamines | 1 | 2002 | 152 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 1626 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 14672 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2824 | 0.010 |
Why?
|
| Antigens | 1 | 2007 | 1442 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1982 | 167 | 0.010 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 3886 | 0.010 |
Why?
|
| Spiperone | 2 | 1991 | 31 | 0.010 |
Why?
|
| Isoproterenol | 2 | 1972 | 398 | 0.010 |
Why?
|
| Temperature | 1 | 1987 | 2232 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 1893 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9551 | 0.010 |
Why?
|
| Dosage Forms | 1 | 1980 | 55 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2000 | 26396 | 0.010 |
Why?
|
| Calcium | 1 | 2013 | 5792 | 0.010 |
Why?
|
| Organ Size | 1 | 2005 | 2264 | 0.010 |
Why?
|
| Atrophy | 1 | 2005 | 1631 | 0.010 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 2811 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 1135 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 2000 | 435 | 0.010 |
Why?
|
| Manuals as Topic | 3 | 1985 | 99 | 0.010 |
Why?
|
| Verbal Learning | 1 | 2002 | 459 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1980 | 861 | 0.010 |
Why?
|
| Bronchi | 1 | 1984 | 847 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1980 | 355 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2000 | 54886 | 0.010 |
Why?
|
| Research | 1 | 1988 | 1977 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 2000 | 616 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1984 | 1830 | 0.010 |
Why?
|
| Epinephrine | 1 | 2002 | 782 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 1479 | 0.010 |
Why?
|
| Nerve Net | 1 | 2010 | 2307 | 0.010 |
Why?
|
| Amphetamine | 1 | 1979 | 222 | 0.010 |
Why?
|
| Risk Factors | 5 | 2013 | 74886 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1990 | 4522 | 0.010 |
Why?
|
| Obesity | 2 | 2016 | 13085 | 0.010 |
Why?
|
| Family Health | 1 | 2002 | 1254 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 4629 | 0.010 |
Why?
|
| Models, Structural | 1 | 1996 | 339 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 17608 | 0.010 |
Why?
|
| Models, Biological | 2 | 2003 | 9464 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 2586 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 2227 | 0.010 |
Why?
|
| Binding Sites | 1 | 1984 | 6014 | 0.010 |
Why?
|
| Acetazolamide | 1 | 1995 | 98 | 0.010 |
Why?
|
| Contrast Media | 2 | 2001 | 5329 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2011 | 8068 | 0.010 |
Why?
|
| Heroin Dependence | 1 | 1996 | 173 | 0.010 |
Why?
|
| Fluorine Radioisotopes | 1 | 1998 | 405 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 2408 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 4539 | 0.010 |
Why?
|
| Body Weight | 1 | 1985 | 4627 | 0.010 |
Why?
|
| Smoking | 2 | 1984 | 9081 | 0.010 |
Why?
|
| Hydrocortisone | 3 | 1990 | 1840 | 0.010 |
Why?
|
| Curriculum | 1 | 2007 | 3786 | 0.010 |
Why?
|
| Diagnosis, Differential | 5 | 1994 | 12986 | 0.010 |
Why?
|
| Child | 4 | 2005 | 80771 | 0.010 |
Why?
|
| Amino Acid Isomerases | 1 | 1992 | 31 | 0.010 |
Why?
|
| Bupropion | 1 | 1994 | 303 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 8535 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 14766 | 0.010 |
Why?
|
| Hydrotherapy | 1 | 1972 | 6 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 4052 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1998 | 1263 | 0.010 |
Why?
|
| Retrospective Studies | 4 | 1994 | 81659 | 0.010 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 1992 | 97 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 1996 | 771 | 0.010 |
Why?
|
| Physiology | 1 | 1972 | 112 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1995 | 988 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1998 | 2345 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 705 | 0.010 |
Why?
|
| Autopsy | 1 | 1994 | 1011 | 0.010 |
Why?
|
| Diet | 1 | 2008 | 8089 | 0.010 |
Why?
|
| Placebo Effect | 1 | 1994 | 516 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 1550 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1996 | 1592 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1990 | 139 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1987 | 7868 | 0.010 |
Why?
|
| Patient Selection | 1 | 2002 | 4256 | 0.010 |
Why?
|
| Sound | 1 | 1972 | 257 | 0.010 |
Why?
|
| Quinuclidinyl Benzilate | 1 | 1988 | 19 | 0.010 |
Why?
|
| Sputum | 1 | 1972 | 514 | 0.010 |
Why?
|
| Tranylcypromine | 1 | 1988 | 30 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 1988 | 155 | 0.000 |
Why?
|
| Methods | 1 | 1969 | 1065 | 0.000 |
Why?
|
| Receptors, Muscarinic | 1 | 1988 | 156 | 0.000 |
Why?
|
| Injections, Intramuscular | 1 | 1989 | 551 | 0.000 |
Why?
|
| Corpus Callosum | 1 | 1992 | 752 | 0.000 |
Why?
|
| Electrocardiography | 1 | 2001 | 6409 | 0.000 |
Why?
|
| Trazodone | 1 | 1987 | 67 | 0.000 |
Why?
|
| Receptors, Dopamine D1 | 1 | 1988 | 276 | 0.000 |
Why?
|
| Yohimbine | 1 | 1987 | 63 | 0.000 |
Why?
|
| Membranes | 1 | 1987 | 164 | 0.000 |
Why?
|
| Ultraviolet Rays | 1 | 1972 | 1101 | 0.000 |
Why?
|
| Benzazepines | 1 | 1988 | 307 | 0.000 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 1987 | 201 | 0.000 |
Why?
|
| Phosphatidylinositols | 1 | 1987 | 280 | 0.000 |
Why?
|
| Factitious Disorders | 1 | 1985 | 39 | 0.000 |
Why?
|
| Substance-Related Disorders | 2 | 1996 | 4422 | 0.000 |
Why?
|
| Lung | 1 | 1984 | 10076 | 0.000 |
Why?
|
| Locus Coeruleus | 1 | 1987 | 241 | 0.000 |
Why?
|
| Electrochemistry | 1 | 1984 | 144 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 2551 | 0.000 |
Why?
|
| Incidence | 1 | 2002 | 21526 | 0.000 |
Why?
|
| Histrionic Personality Disorder | 1 | 1983 | 10 | 0.000 |
Why?
|
| Pregnancy | 1 | 1984 | 30238 | 0.000 |
Why?
|
| Hypnotics and Sedatives | 1 | 1989 | 1193 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1992 | 4560 | 0.000 |
Why?
|
| Peptides | 1 | 1992 | 4348 | 0.000 |
Why?
|
| Respiratory Sounds | 1 | 1984 | 702 | 0.000 |
Why?
|
| Plasma | 1 | 1982 | 583 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1992 | 4925 | 0.000 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1984 | 1243 | 0.000 |
Why?
|
| United States | 1 | 1986 | 72971 | 0.000 |
Why?
|
| Asthma | 1 | 1972 | 6268 | 0.000 |
Why?
|